Cytokinetics (CYTK) Morgan Stanley 24th Annual Global Healthcare Conference summary

Key launch insights and performance

• MYQORZO launch is progressing with strong momentum, targeting over 50% new patient preference share by year-end, driven by ease of use, flexibility, and differentiated REMS risk mitigation.

• Over half of prescribers are either new to CMI or had not prescribed recently, indicating successful market expansion and physician comfort with the product.

• Repeat prescribing is evident, with new prescribers averaging three prescriptions and strong patient adherence and compliance.

• Time from prescription to reimbursement has improved to about three weeks, supporting rapid revenue conversion.

• Market access barriers are being reduced, with parity expected by year-end, further supporting share gains.

Physician engagement and market strategy

• Focused efforts on educating lower decile physicians and expanding beyond centers of excellence are key to increasing share.

• Differentiation, REMS process, and market access are critical drivers for adoption, especially among less familiar prescribers.

• 30% of prescribers are CMI-naive, contributing significantly to market growth.

• The sales force is addressing friction points and supporting broader adoption, particularly in general cardiology.

• Ongoing evolution of the REMS program is lowering barriers and increasing comfort among community cardiologists.

International expansion and financial outlook

• MYQORZO has launched in Germany, with launches in the UK by year-end and other European countries next year.

• Europe is expected to represent 15%-20% of the global MYQORZO opportunity, despite lower pricing compared to the US.

• The company aims to build a profitable business in both oHCM and nHCM indications in Europe.